Scavenger receptor cysteine-rich protein superfamily (SRCRSF) domains are found in many cell surface molecules and some secreted proteins. Members of the SRCRSF include the macrophage scavenger receptor type I, the speract receptor, complement factor I and the leukocyte antigens CD5, CD6, M130 and WC1 (Resnick et al., 1994) . The 3D structure(s) of SRCR domains are currently unknown and specific functions of SRCR domains are not well understood.
Introduction
Scavenger receptor cysteine-rich protein superfamily (SRCRSF) domains are found in many cell surface molecules and some secreted proteins. Members of the SRCRSF include the macrophage scavenger receptor type I, the speract receptor, complement factor I and the leukocyte antigens CD5, CD6, M130 and WC1 (Resnick et al., 1994) . The 3D structure(s) of SRCR domains are currently unknown and specific functions of SRCR domains are not well understood.
We focused this study of the structure and function of SRCR domains on CD6, which is expressed on mature T cells, some B cells and in the brain (Reinherz et al., 1982; Aruffo et al., 1991) . CD6 has been implicated as a costimulatory T cell molecule (Vollger et al., 1987; Morimoto et al., 1988) . The extracellular region of CD6 contains three SRCR domains of 100 residues each and a stalk region. This is followed by a transmembrane domain and an alternatively spliced cytoplasmic region (Aruffo et al., 1991; Robinson et al., 1995) .
CD6 is one of very few SRCRSF members for which a ligand has been identified (Wee et al., 1994; Bowen et al., 1995; Patel et al., 1995) . This ligand was named activated leukocyte cell adhesion molecule (ALCAM) and is a member of the immunoglobulin superfamily (IgSF) (Williams and Barclay, 1988) . ALCAM is expressed on a variety of immune cells and in the brain. Although the physiological significance of the CD6-ALCAM interaction remains to be elucidated, this interaction has been shown to mediate thymocyte-thymic epithelial cell adhesion Patel et al., 1995) .
Studies with soluble recombinant forms of CD6 and ALCAM have shown that the membrane proximal SRCR domain of CD6 (CD6D3) specifically binds to the N-terminal Ig-domain of ALCAM with 1:1 stoichiometry (Whitney et al., 1995; Bowen et al., 1996) . Several ALCAM residues were identified by mutagenesis as important for the interaction with CD6 (Skonier et al., 1996) . An initial mutagenesis study on CD6D3 aimed at the identification of residues which are important for ligand binding. Fifteen mutants were tested and two residues were identified which, when mutated, affect ALCAM but not anti-CD6D3 mAb binding (Bodian et al., 1997) .
We have now extended the CD6D3 mutagenesis analysis. The focal point of this study was to generate a comprehensive classification of CD6D3 residues as important for structural integrity and/or ligand binding or, alternatively, as permissive to change. Therefore, previously unmutated residues were targeted and 13 new mutants were tested for ligand and mAb binding in ELISA assays and by surface plasmon resonance. Together with previously mutated residues, these residues span the entire SRCR domain. Mutated residues were analyzed in the light of SRCR domain sequence comparison and a total of 21 residues throughout CD6D3 could be classified based on unambiguous binding profiles of their mutants. In the absence of a three-dimensional structure of an SRCR domain, this classification provides a guideline for mutagenesis studies on other SRCR proteins. Once a structure becomes available, the mAb and ligand binding profiles of these mutants will also provide a database for SRCR domain structure-function analysis.
Materials and methods
A previously generated alignment of CD6D3 with 26 SRCR domain sequences from ten SRCRSF proteins (Bodian et al., 1997) was used to select residues for mutagenesis and to map residues according to their importance for structural integrity or ALCAM binding. Briefly, SRCR domain sequences were extracted from the PIR, Swissprot and GenPept databases and aligned using Pileup (Feng and Doolittle, 1987) . The alignment was manually modified to match corresponding cysteine positions and to accommodate insertions/deletions in regions of high sequence diversity. Only B set SRCR domain sequences (Resnick et al., 1994) with clear similarity to CD6D3 were included in the comparison.
Point mutations and diagnostic restriction sites were introduced in CD6D3 including the stalk region (CD6D3S) and inserted into the plasmids CDM7B-or PD19, both of which include the constant and hinge regions of human IgG 1 (Hollenbaugh et al., 1995) . Mutants were introduced using the QuikChange mutagenesis procedure (Stratagene) or generated by overlap extension PCR (Bajorath et al., 1995) . Mutated CDM7B-plasmids were transformed by electroporation into competent MC1061 cells, followed by AmpTet selection. The mutated PD19 vector was heat shock transformed into supercompetent XL-1 blue cells (Stratagene), followed by Amp selection. The sequence of the entire CD6D3S coding region was confirmed for each mutant by cDNA sequencing. Mutant fusion proteins were produced by transient expression in COS cells (Bajorath et al., 1995) . Some purified mutant proteins and wild-type CD6D3 were tested by native and SDS-PAGE. No differences between mutant proteins and wild-type were apparent. Four anti-CD6D3 murine mAbs (A, B, C, D) (Bodian et al., 1997) , which did not show reactivity in Western blots, were used to assess the gross conformational integrity of CD6D3 mutant proteins.
Similar ELISA assays were used to determine mutant protein concentrations in cell culture supernatants and to test mAb and ALCAM binding. Immulon-2 96-well plates (Dynatech Labs) were coated with goat anti-human IgG (Jackson ImmunoResearch) at 4°C overnight. Wells were washed with PBS-0.05% Tween, then incubated in 1 EIA diluent (Genetic Systems) for 1 h at room temperature (RT) and washed again. Filtered supernatants containing the mutant proteins were serially diluted with EIA and incubated on the plates for 1 h at RT. An Ig fusion protein containing the three N-terminal domains of ALCAM at known concentration was used as a standard for the determination of protein concentration. After washing, HRP-conjugated donkey antihuman IgG (Jackson ImmunoResearch), diluted 1:2000 in EIA, was added to each well and plates were incubated for 1 h at RT. Plates were then developed by the addition of 70 µl of TMB-diluted solution (Genetic Systems) and reactions were stopped after 10 or 15 min at RT by the addition of 70 µl of 0.5 M H 2 SO 4 . The OD 450/630 nm ratio was determined for each well and averaged over triplicate samples.
To monitor mAb binding, dilutions of hybridoma cell supernatants containing anti-CD6D3 mAbs were added to plates coated with serial dilutions of mutant proteins and incubated for 1 h at RT. Plates were washed in PBS-Tween, followed by incubation of goat anti-mouse IgG-HRP (Southern Biotechnology Associates). To test ALCAM binding, a fusion protein consisting of full-length ALCAM and mouse IgG was used at 1 µg/ml instead of anti-CD6D3 mAbs.
ALCAM binding to CD6 mutant proteins was also assayed by surface plasmon resonance analysis (Jönsson et al., 1991) using the BIAcore (Biacore, Uppsala, Sweden). Amine coupling chemistry (Karlsson et al., 1991) was used to immobilize ALCAM-Ig on the CM5 sensor chip. Filtered cell culture supernatants containing CD6D3 mutant proteins were injected using phosphate-buffered saline as running buffer. The dissociation of bound protein was measured. The data were fitted to an exponential decay to obtain dissociation (off-)rates.
Results and discussion
Residue selection and mutagenesis Two groups of SRCR domains, A and B, were defined based on cysteine patterns and some other conserved residues (Resnick et al., 1994) . Group A sequences contain mostly six 944 cysteines and group B sequences eight. CD6D3 belongs to the B set. In Figure 1 , a comparison of a subset of group B SRCR domain sequences is shown. The N-terminal half of these SRCR domains includes segments of high residue conservation, while the C-terminal half is much less conserved. Conserved and non-conserved residues throughout CD6D3 were selected for mutagenesis and drastic mutations to charged residues were introduced. In the case of structurally or functionally significant residues, these mutations were expected to compromise CD6D3 structure or ligand binding to an extent detectable by mAb and/or ALCAM binding assays. Fourteen mutants were generated. The targeted residues are shown in Table I .
Mutant proteins CD6D3 point mutants were transiently expressed in COS cells as soluble Ig fusion proteins. One of 14 mutant proteins (M326R) was not expressed in quantities detectable by ELISA or SDS-PAGE (Table I ). The expressed mutant proteins were first tested for their ability to bind to four conformationally sensitive anti-CD6D3 mAbs.
Monoclonal antibody binding
To assess the structural integrity of the mutant proteins, binding to four conformationally sensitive mAbs was tested. As shown previously, comparison of mAb binding profiles of mutant proteins allows the detection of structural defects, if several conformationally dependent mAbs are available (Bajorath et al., 1995) . The main advantages of mAb binding over biophysical methods such as circular dichroism are that robust ELISA assays can be developed to compare binding of mutant proteins to wild-type, that relatively low protein concentrations are sufficient and that the results are much less dependent on contaminations. These aspects are particularly important if many mutant proteins need to be tested and compared, as in the present study. The main disadvantage of the mAb binding approach is that the generation of a panel of mAbs with suitable binding characteristics is time consuming and often difficult. Figure 2 shows representative mAb binding experiments. In these binding experiments, which are summarized in Table I , different binding profiles were observed. Some mutants failed to bind to any of the mAbs (e.g. F344R), while others consistently bound to all mAbs similar to wild-type (e.g. N348R) or at reduced levels (e.g. R314E). Two mutants (P296R and E333K) bound strongly to only one or two mAbs.
Failure to bind to mAbs may be due to misfolding, significant conformational changes and/or aggregation of mutant proteins. Alternatively, a mutation may disrupt the epitope of one or more of these mAbs. For example, mutants P296R and E333K bound ALCAM similarly to wild-type (Table I ; see below) but did not show consistent mAb binding. This suggests that these mutations predominantly affect mAb epitopes and not 3D structure or ligand binding. With these exceptions, only mutant proteins which consistently bound at wild-type levels to all four mAbs were considered structurally intact, whereas residues whose mutation resulted in reduced or abolished mAb and ligand binding were considered important for the 3D structural integrity of CD6D3. Figure 3 shows the results of representative ELISA experiments in which the binding of soluble CD6D3 mutant proteins to immobilized ALCAM-Ig was assayed. All ligand binding experiments are summarized in Table I . Q304E which consistently bound to mAbs at wild-type levels also bound ligand like CD6D3. In contrast, F344R which did not show mAb binding also failed to bind ligand, suggesting that the structure of the protein was severely compromised as a consequence of this mutation. Similarly, R314E displayed partially reduced binding to both mAbs and ALCAM, indicating the presence of a conformational defect, albeit of lesser magnitude than in F344R. Mutant protein N348R consistently bound to mAbs like 945 wild-type CD6D3, but showed significantly reduced ALCAM binding (Figure 3 ). This indicated that this residue is important for ligand binding and not structural integrity. Taken together, the results demonstrate that ALCAM binding requires intact 3D structure of CD6D3, since mutants which were not recognized by the conformationally sensitive mAbs did not bind ligand. 
ALCAM binding by ELISA
'Not critical' means that mutation of this residue did not affect mAb or ALCAM binding. 'Structure' indicates that mutation of this residue significantly perturbed the 3D structure of CD6D3, as monitored by binding of conformationally sensitive mAbs. 'Ligand binding' means that this residue is only important for ligand binding and not overall structural integrity. Residues labeled with asterisks (*) were classified based on experiments reported by Bodian et al. (1997) .
BIAcore analysis
To characterize the binding of mutant proteins to ALCAM in more detail, kinetic off-rates of binding were determined using the surface plasmon resonance technique (Jönsson et al., 1991) .
In these experiments, ALCAM-Ig fusion protein was immobilized on the sensor chip and the binding to mutant proteins was monitored. Representative binding experiments are shown in Figure 4 . The binding of mutant proteins occurs during the Table I . association phase, which is followed by the dissociation of bound protein. Binding levels are dependent on the protein concentration in the mobile phase, while the off-rates are independent of concentration.
The results obtained were consistent with the ELISA data. Mutant proteins which failed to bind ALCAM in ELISA did not show detectable binding on the BIAcore (e.g. F344R and N348R). Other mutants showed wild-type-like binding in both ELISA and BIAcore assays (e.g. P296R). Mutant Q304E showed binding levels comparable to CD6D3 and a slightly faster off-rate (4.310 -3 s -1 ) than wild-type (8.210 -4 s -1 ) (Figure 4 ). Other mutant proteins (K316E and L322R) had similar off-rates but consistently reduced binding levels by BIAcore. Mutant R314E which showed reduced binding to ALCAM in ELISA did not show detectable BIAcore binding ( Table I) .
Classification of residues
Based on the observed binding characteristics of the mutant proteins (Table I) , seven residues were classified as critical for structural integrity, four residues as not important for structure or ligand binding and one residue (N348) as critical for ligand recognition. Residues which, when mutated, did not affect structural integrity of ligand binding are presumably surface exposed residues which are located outside the ALCAM binding site.
Previously, other CD6D3 residues were subjected to equivalent mutagenesis experiments and mAb/ligand binding assays (Bodian et al., 1997) . The primary goal of this study was to identify residues important for CD6 ligand binding. The results of these experiments were taken into account to classify residues according to their importance for structure and binding. Taken together, a total of 21 residues were classified. The classification of residues is shown in Table II . Residues were not classified when the mutant binding profiles showed ambiguities such as for K316E in our present and N345D and N345Q in our previous study.
Mapping of residues
The residue classification was combined with the SRCR domain sequence comparison (Figure 1 ). Residues which are tolerant to mutations or, alternatively, structurally important are found throughout CD6D3. As expected, some residues which are conserved in different SRCR domains (e.g. W286) are important for structural integrity. However, the presence of structurally important residues is not limited to conserved segments. Seven residues whose mutations resulted in detectable structural perturbations map to the C-terminal half of the SRCR domains, which is much less conserved than the Nterminal region.
Residues important for ligand binding are conserved in human and murine CD6D3, consistent with the finding that CD6 and ALCAM show cross-species binding (Whitney et al., 1995) . These residues map to a region close to the C-terminus which shows little sequence conservation. This segment also includes four residues which are important for structural integrity. This suggests that this C-terminal region is particularly important for the structure and binding properties of CD6D3.
Conclusions
Site-directed mutagenesis experiments on the CD6 ligand binding domain (CD6D3) in conjunction with mAb and ligand binding assays have identified CD6D3 residues which either 947 tolerate drastic mutations or, alternatively, are relevant for structural integrity or ALCAM binding. A region close to the C-terminus has been identified as particularly important for the 3D structural integrity of CD6D3 and binding to ALCAM. In the absence of a 3D structure of an SRCR domain, our mutagenesis and binding analysis has provided a database of mutants and a classification of CD6 residues according to their importance for structure or ligand binding. These results are expected to aid in the design of similar studies of other SRCR proteins.
